COMMUNIQUÉ DE PRESSE publié le 20/03/2024 à 09:50, il y a 7 mois 19 jours MindBio Begins Landmark Phase 2B Take-Home Microdosing (MB22001) Clinical Trial in Patients with Major Depressive Disorder Phase 2B trial begins with MB22001 for Major Depressive Disorder patients. Successful Phase 2A trial showed 53% in remission with 14.1 MADRS score drop. MindBio aims to scale up psychedelic treatment for depression MB22001 Major Depressive Disorder Phase 2b MindBio Psychedelic Treatment
COMMUNIQUÉ DE PRESSE publié le 20/03/2024 à 09:50, il y a 7 mois 19 jours MindBio Begins Landmark Phase 2B Take-Home Microdosing (MB22001) Clinical Trial in Patients with Major Depressive Disorder MindBio Therapeutics Corp. commences Phase 2B clinical trial for MB22001 in Major Depressive Disorder patients, following successful Phase 2A trial with significant results Psychedelic Medicine MindBio Therapeutics Corp. MB22001 Major Depressive Disorder Clinical Trial
BRÈVE publiée le 04/03/2024 à 11:05, il y a 8 mois 4 jours MindBio Therapeutics passe à l'essai de phase 2B pour la médecine psychédélique dans le trouble dépressif majeur MindBio Thérapeutique Trouble Dépressif Majeur Essai Clinique De Phase 2B Médecine Psychédélique Microdosage Du LSD
BRÈVE publiée le 04/03/2024 à 11:05, il y a 8 mois 4 jours MindBio Therapeutics Advances to Phase 2B Trial for Psychedelic Medicine in Major Depressive Disorder Psychedelic Medicine Major Depressive Disorder Microdosing LSD Phase 2b Clinical Trial MindBio Therapeutics
COMMUNIQUÉ DE PRESSE publié le 04/03/2024 à 11:00, il y a 8 mois 4 jours MindBio Therapeutics Receives Final Regulatory Approval to Conduct Phase 2B Randomised Controlled Trial Microdosing Mb22001 in Patients Diagnosed with Major Depressive Disorder Ethics and regulatory approvals finalized for world-first take-home use of psychedelic medicine MB22001 in Phase 2B randomized controlled trial for Major Depressive Disorder by MindBio Therapeutics Corp Psychedelic Medicine MB22001 Major Depressive Disorder MindBio Therapeutics Phase 2B Trial
BRÈVE publiée le 26/02/2024 à 10:30, il y a 8 mois 11 jours MindBio annonce des résultats positifs dans un essai clinique de microdosage à domicile pour la dépression Depression MB22001 Essai Clinique MindBio Microdosage
BRÈVE publiée le 26/02/2024 à 10:30, il y a 8 mois 11 jours MindBio Announces Positive Results in At-Home Microdosing Clinical Trial for Depression Depression MB22001 MindBio Microdosing Clinical Test
COMMUNIQUÉ DE PRESSE publié le 26/02/2024 à 10:30, il y a 8 mois 11 jours MindBio Therapeutics Announces Positive Depression Data from World-First Phase 2a Take-Home Microdosing Trial MindBio announces positive top line data from its world-first take-home microdosing depression clinical trial using MB22001. Patients experienced a 60% reduction in depressive symptoms with an impressive mean 14.1 point drop in MADRS score over 8 weeks Psychedelic Medicine Depression MB22001 Clinical Trial MindBio
COMMUNIQUÉ DE PRESSE publié le 14/02/2024 à 10:00, il y a 8 mois 23 jours MindBio Therapeutics Completes World First Take Home Phase 2a Microdosing Depression Trial MindBio Therapeutics Corp. completes landmark Phase 2a clinical trial in Major Depressive Disorder patients with regulatory approvals for take-home use of proprietary microdose LSD MB22001. Phase 2B trial in late-stage cancer patients ongoing. CEO Justin Hanka announces pivotal moment for psychiatric medicine development MindBio Therapeutics Corp. Major Depressive Disorder Clinical Trial Phase 2a LSD Microdosing
COMMUNIQUÉ DE PRESSE publié le 30/01/2024 à 08:10, il y a 9 mois 9 jours MindBio Therapeutics Nears Completion of Landmark Phase 2a LSD Microdosing (MB22001) Clinical Trial in Depressed Patients MindBio Therapeutics Corp. is nearing completion of its Phase 2a clinical trial using MB22001 in patients with Major Depressive Disorder. The company expects top line results to be announced in March 2024. MindBio is conducting trials with regulatory approvals for take-home use of a special form of LSD in microdoses, aiming to treat mental health conditions MindBio Therapeutics Corp. Phase 2a Clinical Trial MB22001 Major Depressive Disorder Microdosing LSD
Publié le 08/11/2024 à 12:32, il y a 4 heures 13 minutes Louis Hachette Group announces the publication of its Information Document for listing on Euronext Growth (Paris)
Publié le 08/11/2024 à 12:32, il y a 4 heures 13 minutes Louis Hachette Group annonce la publication de son Document d’Information en vue de sa cotation sur Euronext Growth (Paris)
Publié le 08/11/2024 à 12:15, il y a 4 heures 31 minutes Louis Hachette Group announces the publication of its Information Document for listing on Euronext Growth (Paris)
Publié le 08/11/2024 à 12:15, il y a 4 heures 31 minutes Louis Hachette Group annonce la publication de son Document d’Information en vue de sa cotation sur Euronext Growth (Paris)
Publié le 08/11/2024 à 08:00, il y a 8 heures 46 minutes DAMARTEX / Droits de vote bruts et réels 31 octobre 2024
Publié le 08/11/2024 à 16:00, il y a 46 minutes MANAMAURI, the High-Quality Energy Drink Brand, Joins EastBridge Global Investments for Major International Expansion
Publié le 08/11/2024 à 15:00, il y a 1 heure 46 minutes Hoverfly Technologies Promotes Steve Topping to Chief Operating Officer
Publié le 08/11/2024 à 15:00, il y a 1 heure 46 minutes The Biltmore Los Angeles Welcomes Matthias Kaiser as New General Manager
Publié le 08/11/2024 à 15:00, il y a 1 heure 46 minutes SustainableIT.org Joins COP29 To Champion Climate Solutions and Responsible AI in Baku, Azerbaijan
Publié le 08/11/2024 à 16:15, il y a 30 minutes CGTN: China vows continued efforts to build Asia-Pacific community with shared future
Publié le 08/11/2024 à 15:46, il y a 59 minutes Original-Research: Koenig & Bauer AG (von Montega AG): Kaufen (zuvor: Halten)
Publié le 08/11/2024 à 15:13, il y a 1 heure 32 minutes Form 8.3 - The Vanguard Group, Inc.: International Paper Company